» Articles » PMID: 36581905

Opsoclonus-myoclonus Syndrome Associated with Pancreatic Neuroendocrine Tumor: a Case Report

Overview
Journal BMC Neurol
Publisher Biomed Central
Specialty Neurology
Date 2022 Dec 29
PMID 36581905
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Opsoclonus-myoclonus syndrome (OMS) is a rare, immune-mediated neurological disorder. In adults, the pathogenesis can be idiopathic, post-infectious or paraneoplastic, the latter etiology belonging to the ever-expanding group of defined paraneoplastic neurological syndromes (PNS). In contrast to other phenotypes of PNS, OMS cannot be ascribed to a single pathogenic autoantibody. Here, we report the first detailed case of paraneoplastic, antibody-negative OMS occurring in association with a pancreatic neuroendocrine tumor (pNET).

Case Presentation: A 33-year-old female presented with a two-week history of severe ataxia of stance and gait, dysarthria, head tremor, myoclonus of the extremities and opsoclonus. Her past medical history was notable for a metastatic pancreatic neuroendocrine tumor, and she was subsequently diagnosed with paraneoplastic opsoclonus-myoclonus syndrome. Further workup did not reveal a paraneoplastic autoantibody. She responded well to plasmapheresis, as she was refractory to the first-line therapy with corticosteroids.

Conclusions: This case expands current knowledge on tumors associated with paraneoplastic opsoclonus-myoclonus syndrome and the age group in which it can occur. It further adds evidence to the effectiveness of plasmapheresis in severe cases of opsoclonus-myoclonus syndrome with a lack of response to first-line therapy.

Citing Articles

Neurological autoimmunity in patients with non-pulmonary neuroendocrine neoplasms: clinical manifestations and neural autoantibody profiles.

Mangioris G, Halfdanarson T, Lennon V, Chang B, Dubey D, Dyck P Eur J Neurol. 2024; 31(6):e16273.

PMID: 38466015 PMC: 11235830. DOI: 10.1111/ene.16273.

References
1.
Hernandez-Echebarria L, Saiz A, Ares A, Tejada J, Garcia-Tunon L, Nieves C . Paraneoplastic encephalomyelitis associated with pancreatic tumor and anti-GAD antibodies. Neurology. 2006; 66(3):450-1. DOI: 10.1212/01.wnl.0000196488.87746.7b. View

2.
Armangue T, Titulaer M, Sabater L, Pardo-Moreno J, Gresa-Arribas N, Barbero-Bordallo N . A novel treatment-responsive encephalitis with frequent opsoclonus and teratoma. Ann Neurol. 2013; 75(3):435-41. PMC: 4819999. DOI: 10.1002/ana.23917. View

3.
Diaz Diaz A, Hervas Garcia M, Hernandez A . Cerebellar dysfunction and spastic paraparesis associated to anti-Ri antibodies in a patient with a pancreatic neuroendocrine tumor. J Neurooncol. 2016; 130(3):605-606. DOI: 10.1007/s11060-016-2266-y. View

4.
Armangue T, Sabater L, Torres-Vega E, Martinez-Hernandez E, Arino H, Petit-Pedrol M . Clinical and Immunological Features of Opsoclonus-Myoclonus Syndrome in the Era of Neuronal Cell Surface Antibodies. JAMA Neurol. 2016; 73(4):417-24. PMC: 5823978. DOI: 10.1001/jamaneurol.2015.4607. View

5.
Jung K, Youn J, Chung C . Opsoclonus-myoclonus syndrome in an adult with malignant melanoma. J Neurol. 2006; 253(7):942-3. DOI: 10.1007/s00415-006-0026-1. View